Cutaneous Mastocytosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
Increased Awareness, Photochemotherapy Adoption, and Research Investments Drive Growth
The global Cutaneous Mastocytosis Treatment Market is poised for significant expansion, with a projected worth of $395 million by 2031. This growth can be attributed to various factors, including heightened awareness of Cutaneous Mastocytosis, increased adoption of Photochemotherapy, and substantial investments in research and drug development.
Major Drivers of Growth:
• Increasing Awareness About Disease Symptoms: The growth of the Cutaneous Mastocytosis Treatment Market is being fueled by the growing awareness of Cutaneous Mastocytosis, its symptoms, diagnosis, and available treatments. Parents of infants are now more informed about the condition, leading to increased diagnoses and treatment requirements. Non-profit organizations and government entities are actively spreading awareness about Cutaneous Mastocytosis, contributing to market expansion.
• Increased Adoption of Photochemotherapy: While no permanent cure exists for Cutaneous Mastocytosis, Photochemotherapy (PUVA) has emerged as an effective treatment option. This approach combines Psoralens with long-wave ultraviolet radiation and is gaining popularity among medical practitioners. The promising results of Photochemotherapy are driving its increased use, further boosting the market.
• Increasing Investment In Research And Drug Development: Major market players are investing significantly in research and drug development to discover innovative treatment options for Cutaneous Mastocytosis. This investment aims to improve disease management through novel diagnostic and prognostic factors, creating opportunities for market expansion.
Challenges Ahead:
High Cost Of Treatment And Medication: Despite the absence of a cure, the cost of treating Cutaneous Mastocytosis and the medications required to alleviate symptoms are prohibitively expensive. Photochemotherapy, a favored treatment option, necessitates 10 to 15 sessions per month, which is financially burdensome for many middle and low-income families. Additionally, the adverse effects of various treatment drugs pose challenges to market growth.
Impact of Covid-19 Pandemic:
Decrease in Consultations for Treatment: The COVID-19 pandemic had a negative impact on the Cutaneous Mastocytosis Treatment Market, resulting in a decline in hospital consultations for treatment. However, with the easing of Covid-19 restrictions in the latter half of 2021, the number of patients seeking treatment has started to rebound.
Competitive Analysis
The Cutaneous Mastocytosis Treatment Market is characterized by fragmentation and is dominated by prominent pharmaceutical companies boasting diverse product portfolios. With no cure currently available, these market players are actively engaged in researching novel treatment options. Notably, major players are leveraging mergers, acquisitions, and collaborations with small and medium-sized companies to expand their market share.
Key Companies Profiled:
• Bausch Health Companies Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Sanofi
• EPI Health, LLC.
• kaleo, Inc.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Mallinckrodt
• Bayer AG
• Johnson & Johnson
Cutaneous Mastocytosis Treatment Market Categorization
Cutaneous Mastocytosis Treatment Market by Drug Class
• Antihistamines
• Steroids
• Mast Cell Stabilizers
• Adrenergic Agonists
• Psoralens (Methoxsalen)
• Others
Cutaneous Mastocytosis Treatment Market by Route of Administration
• Oral,
• Injectables
• Topical
• Others
Cutaneous Mastocytosis Treatment Market by Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA)
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.
- 1. Executive Summary
- 1.1. Global Cutaneous Mastocytosis Treatment Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2023
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Global Cutaneous Mastocytosis Treatment Market Outlook, 2018 – 2031
- 3.1. Global Cutaneous Mastocytosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 – 2031
- 3.1.1. Key Highlights
- 3.1.1.1. Antihistamines
- 3.1.1.2. Steroids
- 3.1.1.3. Mast Cell Stabilizers
- 3.1.1.4. Adrenergic Agonists
- 3.1.1.5. Psoralens (Methoxsalen)
- 3.1.1.6. Others
- 3.2. Global Cutaneous Mastocytosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 3.2.1. Key Highlights
- 3.2.1.1. Oral
- 3.2.1.2. Injectables
- 3.2.1.3. Topical
- 3.2.1.4. Others
- 3.3. Global Cutaneous Mastocytosis Treatment Market Outlook, by Indication Type, Value (US$ Mn), 2018 – 2031
- 3.3.1. Key Highlights
- 3.3.1.1. Maculopapular Cutaneous
- 3.3.1.1.1. Monomorphic
- 3.3.1.1.2. Polymorphic
- 3.3.1.2. Diffuse Cutaneous
- 3.3.1.3. Solitary Cutaneous
- 3.4. Global Cutaneous Mastocytosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 3.4.1. Key Highlights
- 3.4.1.1. Hospital Pharmacies
- 3.4.1.2. Retail Pharmacies
- 3.4.1.3. Drug Stores
- 3.4.1.4. Online Pharmacies
- 3.5. Global Cutaneous Mastocytosis Treatment Market Outlook, by Region, Value (US$ Mn), 2018 – 2031
- 3.5.1. Key Highlights
- 3.5.1.1. North America
- 3.5.1.2. Europe
- 3.5.1.3. Asia Pacific
- 3.5.1.4. Latin America
- 3.5.1.5. Middle East & Africa
- 4. North America Cutaneous Mastocytosis Treatment Market Outlook, 2018 – 2031
- 4.1. North America Cutaneous Mastocytosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 – 2031
- 4.1.1. Key Highlights
- 4.1.1.1. Antihistamines
- 4.1.1.2. Steroids
- 4.1.1.3. Mast Cell Stabilizers
- 4.1.1.4. Adrenergic Agonists
- 4.1.1.5. Psoralens (Methoxsalen)
- 4.1.1.6. Others
- 4.2. North America Cutaneous Mastocytosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 4.2.1. Key Highlights
- 4.2.1.1. Oral
- 4.2.1.2. Injectables
- 4.2.1.3. Topical
- 4.2.1.4. Others
- 4.3. North America Cutaneous Mastocytosis Treatment Market Outlook, by Indication Type, Value (US$ Mn), 2018 – 2031
- 4.3.1. Key Highlights
- 4.3.1.1. Maculopapular Cutaneous
- 4.3.1.1.1. Monomorphic
- 4.3.1.1.2. Polymorphic
- 4.3.1.2. Diffuse Cutaneous
- 4.3.1.3. Solitary Cutaneous
- 4.4. North America Cutaneous Mastocytosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 4.4.1. Key Highlights
- 4.4.1.1. Hospital Pharmacies
- 4.4.1.2. Retail Pharmacies
- 4.4.1.3. Drug Stores
- 4.4.1.4. Online Pharmacies
- 4.4.2. BPS Analysis/Market Attractiveness Analysis
- 4.5. North America Cutaneous Mastocytosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 4.5.1. Key Highlights
- 4.5.1.1. U.S. Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 4.5.1.2. U.S. Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 4.5.1.3. U.S. Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 4.5.1.4. U.S. Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 4.5.1.5. Canada Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 4.5.1.6. Canada Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 4.5.1.7. Canada Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 4.5.1.8. Canada Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis
- 5. Europe Cutaneous Mastocytosis Treatment Market Outlook, 2018 – 2031
- 5.1. Europe Cutaneous Mastocytosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.1.1. Key Highlights
- 5.1.1.1. Antihistamines
- 5.1.1.2. Steroids
- 5.1.1.3. Mast Cell Stabilizers
- 5.1.1.4. Adrenergic Agonists
- 5.1.1.5. Psoralens (Methoxsalen)
- 5.1.1.6. Others
- 5.2. Europe Cutaneous Mastocytosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.2.1. Key Highlights
- 5.2.1.1. Oral
- 5.2.1.2. Injectables
- 5.2.1.3. Topical
- 5.2.1.4. Others
- 5.3. Europe Cutaneous Mastocytosis Treatment Market Outlook, by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.3.1. Key Highlights
- 5.3.1.1. Maculopapular Cutaneous
- 5.3.1.1.1. Monomorphic
- 5.3.1.1.2. Polymorphic
- 5.3.1.2. Diffuse Cutaneous
- 5.3.1.3. Solitary Cutaneous
- 5.4. Europe Cutaneous Mastocytosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.4.1. Key Highlights
- 5.4.1.1. Hospital Pharmacies
- 5.4.1.2. Retail Pharmacies
- 5.4.1.3. Drug Stores
- 5.4.1.4. Online Pharmacies
- 5.4.2. BPS Analysis/Market Attractiveness Analysis
- 5.5. Europe Cutaneous Mastocytosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 5.5.1. Key Highlights
- 5.5.1.1. Germany Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.5.1.2. Germany Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.5.1.3. Germany Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.5.1.4. Germany Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.1.5. U.K. Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.5.1.6. U.K. Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.5.1.7. U.K. Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.5.1.8. U.K. Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.1.9. France Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.5.1.10. France Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.5.1.11. France Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.5.1.12. France Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.1.13. Italy Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.5.1.14. Italy Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.5.1.15. Italy Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.5.1.16. Italy Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.1.17. Turkey Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.5.1.18. Turkey Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.5.1.19. Turkey Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.5.1.20. Turkey Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.1.21. Russia Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.5.1.22. Russia Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.5.1.23. Russia Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.5.1.24. Russia Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.1.25. Rest of Europe Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 5.5.1.26. Rest of Europe Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 5.5.1.27. Rest of Europe Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 5.5.1.28. Rest of Europe Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis
- 6. Asia Pacific Cutaneous Mastocytosis Treatment Market Outlook, 2018 – 2031
- 6.1. Asia Pacific Cutaneous Mastocytosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 – 2031
- 6.1.1. Key Highlights
- 6.1.1.1. Antihistamines
- 6.1.1.2. Steroids
- 6.1.1.3. Mast Cell Stabilizers
- 6.1.1.4. Adrenergic Agonists
- 6.1.1.5. Psoralens (Methoxsalen)
- 6.1.1.6. Others
- 6.2. Asia Pacific Cutaneous Mastocytosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.2.1. Key Highlights
- 6.2.1.1. Oral
- 6.2.1.2. Injectables
- 6.2.1.3. Topical
- 6.2.1.4. Others
- 6.3. Asia Pacific Cutaneous Mastocytosis Treatment Market Outlook, by Indication Type, Value (US$ Mn), 2018 – 2031
- 6.3.1. Key Highlights
- 6.3.1.1. Maculopapular Cutaneous
- 6.3.1.1.1. Monomorphic
- 6.3.1.1.2. Polymorphic
- 6.3.1.2. Diffuse Cutaneous
- 6.3.1.3. Solitary Cutaneous
- 6.4. Asia Pacific Cutaneous Mastocytosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.4.1. Key Highlights
- 6.4.1.1. Hospital Pharmacies
- 6.4.1.2. Retail Pharmacies
- 6.4.1.3. Drug Stores
- 6.4.1.4. Online Pharmacies
- 6.4.2. BPS Analysis/Market Attractiveness Analysis
- 6.5. Asia Pacific Cutaneous Mastocytosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 6.5.1. Key Highlights
- 6.5.1.1. China Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 6.5.1.2. China Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.5.1.3. China Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 6.5.1.4. China Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.5.1.5. Japan Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 6.5.1.6. Japan Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.5.1.7. Japan Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 6.5.1.8. Japan Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.5.1.9. South Korea Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 6.5.1.10. South Korea Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.5.1.11. South Korea Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 6.5.1.12. South Korea Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.5.1.13. India Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 6.5.1.14. India Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.5.1.15. India Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 6.5.1.16. India Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.5.1.17. Southeast Asia Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 6.5.1.18. Southeast Asia Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.5.1.19. Southeast Asia Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 6.5.1.20. Southeast Asia Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.5.1.21. Rest of Asia Pacific Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 6.5.1.22. Rest of Asia Pacific Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 6.5.1.23. Rest of Asia Pacific Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 6.5.1.24. Rest of Asia Pacific Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis
- 7. Latin America Cutaneous Mastocytosis Treatment Market Outlook, 2018 – 2031
- 7.1. Latin America Cutaneous Mastocytosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 – 2031
- 7.1.1. Key Highlights
- 7.1.1.1. Antihistamines
- 7.1.1.2. Steroids
- 7.1.1.3. Mast Cell Stabilizers
- 7.1.1.4. Adrenergic Agonists
- 7.1.1.5. Psoralens (Methoxsalen)
- 7.1.1.6. Others
- 7.2. Latin America Cutaneous Mastocytosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.2.1. Key Highlights
- 7.2.1.1. Oral
- 7.2.1.2. Injectables
- 7.2.1.3. Topical
- 7.2.1.4. Others
- 7.3. Latin America Cutaneous Mastocytosis Treatment Market Outlook, by Indication Type, Value (US$ Mn), 2018 – 2031
- 7.3.1. Key Highlights
- 7.3.1.1. Maculopapular Cutaneous
- 7.3.1.1.1. Monomorphic
- 7.3.1.1.2. Polymorphic
- 7.3.1.2. Diffuse Cutaneous
- 7.3.1.3. Solitary Cutaneous
- 7.4. Latin America Cutaneous Mastocytosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.4.1. Key Highlights
- 7.4.1.1. Hospital Pharmacies
- 7.4.1.2. Retail Pharmacies
- 7.4.1.3. Drug Stores
- 7.4.1.4. Online Pharmacies
- 7.4.2. BPS Analysis/Market Attractiveness Analysis
- 7.5. Latin America Cutaneous Mastocytosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 7.5.1. Key Highlights
- 7.5.1.1. Brazil Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 7.5.1.2. Brazil Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.5.1.3. Brazil Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 7.5.1.4. Brazil Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.5.1.5. Mexico Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 7.5.1.6. Mexico Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.5.1.7. Mexico Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 7.5.1.8. Mexico Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.5.1.9. Argentina Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 7.5.1.10. Argentina Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.5.1.11. Argentina Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 7.5.1.12. Argentina Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.5.1.13. Rest of Latin America Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 7.5.1.14. Rest of Latin America Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 7.5.1.15. Rest of Latin America Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 7.5.1.16. Rest of Latin America Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis
- 8. Middle East & Africa Cutaneous Mastocytosis Treatment Market Outlook, 2018 – 2031
- 8.1. Middle East & Africa Cutaneous Mastocytosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 – 2031
- 8.1.1. Key Highlights
- 8.1.1.1. Antihistamines
- 8.1.1.2. Steroids
- 8.1.1.3. Mast Cell Stabilizers
- 8.1.1.4. Adrenergic Agonists
- 8.1.1.5. Psoralens (Methoxsalen)
- 8.1.1.6. Others
- 8.2. Middle East & Africa Cutaneous Mastocytosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.2.1. Key Highlights
- 8.2.1.1. Oral
- 8.2.1.2. Injectables
- 8.2.1.3. Topical
- 8.2.1.4. Others
- 8.3. Middle East & Africa Cutaneous Mastocytosis Treatment Market Outlook, by Indication Type, Value (US$ Mn), 2018 – 2031
- 8.3.1. Key Highlights
- 8.3.1.1. Maculopapular Cutaneous
- 8.3.1.1.1. Monomorphic
- 8.3.1.1.2. Polymorphic
- 8.3.1.2. Diffuse Cutaneous
- 8.3.1.3. Solitary Cutaneous
- 8.4. Middle East & Africa Cutaneous Mastocytosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.4.1. Key Highlights
- 8.4.1.1. Hospital Pharmacies
- 8.4.1.2. Retail Pharmacies
- 8.4.1.3. Drug Stores
- 8.4.1.4. Online Pharmacies
- 8.4.2. BPS Analysis/Market Attractiveness Analysis
- 8.5. Middle East & Africa Cutaneous Mastocytosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 – 2031
- 8.5.1. Key Highlights
- 8.5.1.1. GCC Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 8.5.1.2. GCC Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.5.1.3. GCC Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 8.5.1.4. GCC Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.5.1.5. South Africa Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 8.5.1.6. South Africa Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.5.1.7. South Africa Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 8.5.1.8. South Africa Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.5.1.9. Egypt Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 8.5.1.10. Egypt Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.5.1.11. Egypt Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 8.5.1.12. Egypt Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.5.1.13. Nigeria Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 8.5.1.14. Nigeria Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.5.1.15. Nigeria Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 8.5.1.16. Nigeria Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.5.1.17. Rest of Middle East & Africa Cutaneous Mastocytosis Treatment Market by Drug Class, Value (US$ Mn), 2018 – 2031
- 8.5.1.18. Rest of Middle East & Africa Cutaneous Mastocytosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 – 2031
- 8.5.1.19. Rest of Middle East & Africa Cutaneous Mastocytosis Treatment Market by Indication Type, Value (US$ Mn), 2018 – 2031
- 8.5.1.20. Rest of Middle East & Africa Cutaneous Mastocytosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 – 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis
- 9. Competitive Landscape
- 9.1. By Drug Class vs Indication Heatmap
- 9.2. Company Market Share Analysis, 2023
- 9.3. Competitive Dashboard
- 9.4. Company Profiles
- 9.4.1. Bausch Health Companies Inc.
- 9.4.1.1. Company Overview
- 9.4.1.2. Product Portfolio
- 9.4.1.3. Financial Overview
- 9.4.1.4. Business Strategies and Development
- 9.4.2. Pfizer Inc.
- 9.4.2.1. Company Overview
- 9.4.2.2. Product Portfolio
- 9.4.2.3. Financial Overview
- 9.4.2.4. Business Strategies and Development
- 9.4.3. Merck & Co., Inc.
- 9.4.3.1. Company Overview
- 9.4.3.2. Product Portfolio
- 9.4.3.3. Financial Overview
- 9.4.3.4. Business Strategies and Development
- 9.4.4. Mylan N.V.
- 9.4.4.1. Company Overview
- 9.4.4.2. Product Portfolio
- 9.4.4.3. Financial Overview
- 9.4.4.4. Business Strategies and Development
- 9.4.5. Sanofi
- 9.4.5.1. Company Overview
- 9.4.5.2. Product Portfolio
- 9.4.5.3. Financial Overview
- 9.4.5.4. Business Strategies and Development
- 9.4.6. Sanofi
- 9.4.6.1. Company Overview
- 9.4.6.2. Product Portfolio
- 9.4.6.3. Financial Overview
- 9.4.6.4. Business Strategies and Development
- 9.4.7. kaleo, Inc.
- 9.4.7.1. Company Overview
- 9.4.7.2. Product Portfolio
- 9.4.7.3. Financial Overview
- 9.4.7.4. Business Strategies and Development
- 9.4.8. Teva Pharmaceutical Industries Ltd.
- 9.4.8.1. Company Overview
- 9.4.8.2. Product Portfolio
- 9.4.8.3. Financial Overview
- 9.4.8.4. Business Strategies and Development
- 9.4.9. Novartis AG
- 9.4.9.1. Company Overview
- 9.4.9.2. Product Portfolio
- 9.4.9.3. Financial Overview
- 9.4.9.4. Business Strategies and Development
- 9.4.10. Mallinckrodt
- 9.4.10.1. Company Overview
- 9.4.10.2. Product Portfolio
- 9.4.10.3. Financial Overview
- 9.4.10.4. Business Strategies and Development
- 9.4.11. Bayer AG
- 9.4.11.1. Company Overview
- 9.4.11.2. Product Portfolio
- 9.4.11.3. Financial Overview
- 9.4.11.4. Business Strategies and Development
- 9.4.12. Johnson & Johnson
- 9.4.12.1. Company Overview
- 9.4.12.2. Product Portfolio
- 9.4.12.3. Financial Overview
- 9.4.12.4. Business Strategies and Development
- 10. Appendix
- 10.1. Research Methodology
- 10.2. Report Assumptions
- 10.3. Acronyms and Abbreviations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook